Annaida Technologies SA Company

Annaida Technologies SA has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance at a scale 10-fold better than existing technologies, enabling non invasive chemical analysis at the scale of a single human embryo. Nuclear opens new global markets in assisted reproductive technology (“ART”), enabling non-invasive embryo viability screening for in vitro fertilization (“IVF”), as well as in biochemical research.
Industry: Reproductive Health & Contraception
Headquarters: Lausanne, Vaud, Switzerland
Founded Date: 06-08-2018
Employees Number: 1-10
Funding Status: Seed
Investors Number: 9
Total Funding: $1,487,439
Last Funding Date: 2020-04-09
Last Funding Type: Seed

Visit Website
Register and Claim Ownership